Casi pharmaceuticals completes redomiciliation merger

Beijing , march 21, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi) ("casi" or the "company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the company as a cayman islands company (the "redomiciliation merger") has been completed. pursuant to the redomiciliation merger, each outstanding share of the common stock of the company was converted into the right to receive one ordinary share of casi pharmaceuticals, inc., a company incorporated under the laws of the cayman islands ("casi cayman").
CASI Ratings Summary
CASI Quant Ranking